Compare AbbVie Inc (ABBV) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Coinbase Global, Inc. — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while Coinbase Global, Inc. trades at $160.05 (market cap $43.08B). The key difference: AbbVie Inc is far larger — about 10.4× Coinbase Global, Inc.'s market cap, and AbbVie Inc pays a 2.72% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | COIN | |
|---|---|---|
Market Cap | $449.91B | $43.08B |
Sector | Health | Technology |
52-Week High | $261.07 | $419.78 |
52-Week Low | $184.85 | $141.09 |
Enterprise Value | $513.38B | $40.36B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
COIN trades at $163.51, down 1.19% over 24 hours, with a bearish technical signal and mixed earnings history. The company reported $7.18B revenue in 2025 with a net income margin of 12.2%, though recent quarters showed misses against EPS expectations. Analyst consensus remains bullish with a $233.08 price target, but cash flow trends indicate potential pressure as operating cash flow declined to $2.4B in 2025 from $2.6B in 2024.
The outlook for COIN hinges on execution amid volatile crypto markets, with 55% of analysts rating it a buy. Key risks include regulatory uncertainty and competitive threats, while institutional adoption growth offers upside. Investors should weigh high valuation multiples against earnings volatility and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
